Scenesse

Generic name: afamelanotide [ A-fa-me-LAN-oh-tide ]
Drug class: Melanocortin receptor agonists

Medically reviewed by Drugs.com on Jan 11, 2024. Written by Cerner Multum.

What is Scenesse?

Scenesse is used in adults with erythropoietic protoporphyria (EPP). EPP is a condition that can cause severe pain or other skin reactions to sunlight or artificial light.

Scenesse is used to help increase the amount of pain-free time you can spend in sunlight or artificial light.

Scenesse may also be used for purposes not listed in this medication guide.

Scenesse side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Scenesse may cause serious side effects. Call your doctor at once if you have:

• severe pain, swelling, or bleeding where the implant was placed;

• new or worsening skin lesions;

• a mole that has changed in size or color; or

• if the implant sticks out of your skin or comes out by itself.

Common side effects of Scenesse may include:

• pain, itching, redness, swelling, bruising, or other irritation where the implant was placed;

• skin changes such as discoloration, scarring, or a hard lump where the implant was placed;

• skin irritation anywhere on your body;

• new moles or hair growth on the skin;

• cough, pain in your mouth or throat;

• dizziness, drowsiness, tiredness;

• nausea; or

• cold symptoms such as stuffy nose, sneezing, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Scenesse may cause skin darkening, especially in moles or freckles. Tell your doctor about any new moles or skin lesions.

Before taking this medicine

Tell your doctor if you are pregnant or breastfeeding.

Scenesse is not approved for use by anyone younger than 18 years old.

How is Scenesse given?

Scenesse is given in a tiny implant inserted under the skin above the front of your hip. You will receive the implant in a clinic or doctor's office once every 2 months.

The implant is inserted using a special tool that pushes the implant into place under your skin. After injecting the implant, your doctor will feel the area to make sure your implant has been correctly placed.

Your skin where the implant was placed will be covered with a bandage. Leave the bandage on for 24 hours.

You may be able to feel the implant through your skin, but it should not cause pain or discomfort. The implant will dissolve in your body over time.

Call your doctor if you think it has come out of place.

Scenesse may cause your skin to become darker, especially any moles or freckles you have. New moles or skin lesions may appear over time. Ask your doctor about skin symptoms to watch for.

Your will need a full-body skin examination every 6 months.

What happens if I miss a dose?

Call your doctor for instructions if you miss a 2-month appointment to receive your next implant.

What happens if I overdose?

Since the Scenesse implant contains a specific amount of the medicine, you are not likely to receive an overdose.

What should I avoid while receiving afamelanotide?

Avoid sunlight or tanning beds. Always wear protective clothing when you are outdoors and use any sunscreen your doctor recommends.

What other drugs will affect Scenesse?

Other drugs may affect Scenesse, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Further information

• Your doctor can provide more information about Scenesse.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2024 Cerner Multum, Inc. Version: 1.01.